Safety and Immunogenicity of HPV Vaccine Administered Intradermally and Intramuscularly Via Needle-Free Injection System
Status:
Withdrawn
Trial end date:
2025-04-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety and immunogenicity of an HPV
Vaccine (Gardasil) delivered by intramuscular needle-free injection and intradermal
needle-free injection. The main question it aims to answer is:
- Is intramuscular and intradermal needle-free injection of Gardasil safe?
- Does intramuscular and intradermal needle-free vaccination with Gardasil illicit an
immune response?
Participants will:
- Receive Gardasil by intramuscular needle-free injection, intradermal needle-free
injection, or needle and syringe injection.
- Provide blood samples
- Complete physical exams
- Complete diaries
Phase:
Phase 2
Details
Lead Sponsor:
PharmaJet, Inc.
Collaborators:
National Cancer Institute (NCI) National Institutes of Health (NIH)